Havn Life Sciences Inc. Announces Launch & Filing of Preliminary Prospectus
June 26th, 2020
Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces launch and filing of its preliminary prospectus. Havn Life is a biotechnology company on a mission to unlock human performance using evidence-informed research. The Company is aimed at improving cognitive performance through the standardized extraction of psychoactive compounds and the development of natural health care products from novel compounds.
“In order for researchers to fully understand the therapeutic potential of psilocybin and how it can be utilized to treat disease and mental conditions, methods must be developed to ensure that researchers have access to safe, standardized, quality-controlled derivatives and formulations,” says Havn Life Co-CEO Susan Chapelle, a former civic politician and recognized thought leader in the Canadian cannabis space who has consulted with senior levels of government, and brings 25 years of leadership experience in the health, non-profit, and private sectors in Canada.
Havn Life has a dedicated research facility (Havn Labs) located in the South Campus of The University of British Columbia (UBC). Through its team of scientists with extensive experience in chemistry and formulation development, Havn Life is standardizing the extraction of psychedelic compounds to support the development of innovative therapies addressing human health.
“At present, the supply in the illicit psychedelic market is primarily provided by small scale growers, about which there is little information available. Scaling agriculture methods is difficult and without foundational methods for growing this genus of mushrooms, it is unknown if these species can be grown at scale. To date, there are no standardized or quality control methods that have been developed for investigators. The standardized methodology is essential for growing, extracting, and synthesizing these compounds.” added Chapelle. “And that is where Havn Life comes in.”
Vic Neufeld, who previously served as CEO of Aphria for five years during its large scale build up to become one of the leading cannabis producers in the world, and serves as a director of Havn Life said: “Canada is uniquely positioned to decriminalize several psychedelic substances through its constitutional framework. The psychedelic industry is poised to disrupt the current pharmaceutical industry and shift the mental health and well-being market towards novel plant-based products. And for this to happen, the market will require these standardized, quality-controlled substances.”
Neufeld also served as CEO of Jamieson Laboratories, Canada’s largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplements, herbs and botanical medicines. Under his leadership, Jamieson grew its market share from 7 to 27 per cent, and sales grew from $20 million annually to over $250 million.
Havn Life’s multi-disciplinary team includes Co-CEO Tim Moore, who has championed start-ups, acquisitions and has over 30 years’ experience in Fortune 500 leadership roles in Canada and USA. He was former CEO of Green Growth Brands, a US multi-state cannabis operator, which also operated over 200 mall-based CBD kiosks and rose from IPO to a peak valuation of over 1.2 billion dollars. Moore is the former President of The Clorox Company of Canada and COO of Synnex Canada.
Dr. Ivan Casselman (Ph.D., FLS) serves as Havn Life’s Chief Psychedelic Officer. Dr. Casselman is an experienced formulation chemist with a strong foundation in nutraceutical formulation and product development. One of the key components to his research has been a focus on ethnography, experiential investigation, and ensuring a comprehensive understanding of the human psychedelic interface.
Alexzander Samuelsson (BSc) serves as Havn Life’s Chief Research Officer. Mr. Samuelsson has developed patented processes in the extraction as well as formulations and product development within the cannabis industry. His experience and focus on extraction, separation, and isolation of novel compounds within plants and fungi to create natural health products will greatly benefit Havn Life in achieving its strategic goals.
Susan Chapelle & Tim Moore
About Havn Life Sciences Inc.
Havn Life Sciences is a biotechnology company on a mission to unlock human performance using evidence-informed research. The company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from novel compounds. Havn Life’s research facility, Havn Labs, is located in the South Campus at The University of British Columbia (UBC).
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.